Faculty Opinions recommendation of Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Receptor Antagonist ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

Faculty Opinions recommendation of Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13198963.14594054 ◽

2011 ◽

Author(s):

Opeolu Adeoye

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

Faculty Opinions recommendation of Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13198963.14542122 ◽

2011 ◽

Author(s):

Luca Longhi ◽

Edoardo Picetti

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)

The Lancet Neurology ◽

10.1016/s1474-4422(11)70108-9 ◽

2011 ◽

Vol 10 (7) ◽

pp. 618-625 ◽

Cited By ~ 326

Author(s):

R Loch Macdonald ◽

Randall T Higashida ◽

Emanuela Keller ◽

Stephan A Mayer ◽

Andy Molyneux ◽

...

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

Yearbook of Cardiology ◽

10.1016/s0145-4145(10)79836-1 ◽

2010 ◽

Vol 2010 ◽

pp. 102-104

Author(s):

W.J. Elliott

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61500-2 ◽

2009 ◽

Vol 374 (9699) ◽

pp. 1423-1431 ◽

Cited By ~ 200

Author(s):

Michael A Weber ◽

Henry Black ◽

George Bakris ◽

Henry Krum ◽

Stuart Linas ◽

...

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Faculty Opinions recommendation of A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1184971.647074 ◽

2009 ◽

Author(s):

Mahboob Rahman

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Faculty Opinions recommendation of A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1184971.746081 ◽

2009 ◽

Author(s):

David Pollock

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

PM308. A phase 3, multicenter randomized double blind placebo controlled study of the opioid receptor antagonist –Odelepran the treatment of alcohol addiction.

The International Journal of Neuropsychopharmacology ◽

10.1093/ijnp/pyw041.308 ◽

2016 ◽

Vol 19 (Suppl_1) ◽

pp. 10-10 ◽

Cited By ~ 1

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Alcohol Addiction ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Opioid Receptor Antagonist

Bosentan, an endothelin-receptor antagonist, in the treatment of pulmonary hypertension in severe chronic obstructive pulmonary disease: a prospective, double-blind, placebo-controlled trial

http://isrctn.org/> ◽

10.1186/isrctn98252311 ◽

2012 ◽

Author(s):

Michael Tamm

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Hypertension ◽

Receptor Antagonist ◽

Pulmonary Disease ◽

Controlled Trial ◽

Chronic Obstructive ◽

Endothelin Receptor ◽

Double Blind ◽

Obstructive Pulmonary Disease ◽

Endothelin receptor antagonist for subarachnoid haemorrhage

10.1002/14651858.cd008354 ◽

2010 ◽

Author(s):

Zhenghong Shi ◽

KeHu Yang ◽

Jia Guo ◽

Jinhui Tian ◽

Lei Jiang

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor